GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Change In Other Working Capital

CytoDyn (STU:296) Change In Other Working Capital : €-0.00 Mil (TTM As of Nov. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Change In Other Working Capital?

CytoDyn's Change In Other Working Capital for the quarter that ended in Nov. 2024 was €-0.00 Mil. It means CytoDyn's Other Working Capital declined by €0.00 Mil from Aug. 2024 to Nov. 2024 .

CytoDyn's Change In Other Working Capital for the fiscal year that ended in May. 2024 was €0.00 Mil. It means CytoDyn's Other Working Capital stayed the same from May. 2023 to May. 2024 .

CytoDyn Change In Other Working Capital Historical Data

The historical data trend for CytoDyn's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Change In Other Working Capital Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoDyn Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CytoDyn Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of CytoDyn's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Change In Other Working Capital
Comparable Companies
MGX CLYM XFOR TELO BMEA RENB PLX PVLA FBRX SEER VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CYDY:USA
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
Website
https://www.cytodyn.com
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines